|
|
- CD19: a biomarker for B cell development, lymphoma diagnosis and . . .
CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling
- CD19 - Lab Results explained | HealthMatters. io
The CD19 antigen (aka B-lymphocyte antigen CD19 or Cluster of Differentiation 19) plays an important role in clinical oncology It’s a protein found on the surface of B-cells, a type of white blood cell
- CD19 - an overview | ScienceDirect Topics
CD19 antigen, a transmembrane glycoprotein of the immunoglobulin (Ig) superfamily, is encoded by the CD19 gene localized on 16p11 2 It aids in the stimulation of B cells and the development of an immunological response (Wang, Wei, Liu, 2012)
- Pathology Outlines - CD19
Defects in CD19 cause immunodeficiency common variable type 3 (OMIM #613493), characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen
- CD19 – MyPathologyReport
CD19 is a protein primarily expressed on the surface of B cells, a type of white blood cell that plays a key role in the immune system’s defense against infections
- BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 . . .
Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and
- Efficacy and safety of a novel CD19, CD22 dual-targeted fully human . . .
Background Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have demonstrated promising efficacy in treating refractory or relapsed B-cell malignancies Nonetheless, challenges such as antigen escape-mediated relapse and toxicities, including cytokine release syndrome (CRS) and neurotoxicity, may impede their clinical application Methods In this study, we developed a fully
- Researchers identify key B-cell lymphoma traits linked with greatest . . .
HOUSTON, JUNE 18, 2025 ― In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels of benefit from CD19 chimeric antigen receptor (CAR) T cell therapy
|
|
英文每年常用名排名
2023 年排名
2022 年排名
2021 年排名
2020 年排名
2019 年排名
2018 年排名
2017 年排名
2016 年排名
2015 年排名
2014 年排名
2013 年排名
2012 年排名
2011 年排名
2010 年排名
2009 年排名
2008 年排名
2007 年排名
2006 年排名
2005 年排名
2004 年排名
2003 年排名
2002 年排名
2001 年排名
2000 年排名
英文名字起源
希伯来
希腊
条顿
印度
拉丁
拉丁语
古英语
英格兰
阿拉伯
法国
盖尔
英语
匈牙利
凯尔特
西班牙
居尔特
非洲
美洲土著
挪威
德国
威尔士
斯拉夫民族
古德语
爱尔兰
波斯
古法语
盎格鲁撒克逊
意大利
盖尔语
未知
夏威夷
中古英语
梵语
苏格兰
俄罗斯
土耳其
捷克
希腊;拉丁
斯干那维亚
瑞典
波兰
乌干达
拉丁;条顿
巴斯克语
亚拉姆
亚美尼亚
斯拉夫语
斯堪地纳维亚
越南
荷兰
|